BioXcel Therapeutics (BTAI) Price to Sales (2022 - 2026)

BioXcel Therapeutics has reported Price to Sales for 5 years, with the latest figure at 242.53 in Q2 2026.

• On a quarterly basis, Price to Sales rose 142.89% year-over-year to 242.53 in Q2 2026; TTM through Jun 2026 was 59.49, a 330.94% increase from a year earlier, with the FY2025 full-year figure at 30.42, up 354.79% from the prior year.
• Price to Sales was 242.53 for Q2 2026 at BioXcel Therapeutics, up from 176.12 in the prior quarter.
• The five-year high for Price to Sales was 2635.95 in Q1 2023, with the low at 41.42 in Q4 2024.
• Average Price to Sales over 5 years is 617.28, with a median of 196.65 recorded in 2026.
• The sharpest annual moves came in 2024 and 2025: Price to Sales tumbled 93.82% in 2024, then soared 206.38% in 2025.
• Over 5 years, Price to Sales stood at 2540.33 in 2022, then sank by 90.76% to 234.82 in 2023, then plunged by 82.36% to 41.42 in 2024, then jumped by 84.22% to 76.3 in 2025, then surged by 217.86% to 242.53 in 2026.
• The last three Price to Sales figures came in at 242.53 (Q2 2026), 176.12 (Q1 2026), and 76.3 (Q4 2025), per Business Quant data.